Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma

Journal of Hepatology

Volumn 49, Issue 2, 2008, Pages 207-216

  Nishino, Ryuhei ^a   Honda, Masao ^a   Yamashita, Taro ^a   Takatori, Hajime ^a   Minato, Hiroshi ^b   Zen, Yoh ^b   Sasaki, Motoko ^a   Takamura, Hiroyuki ^a   Horimoto, Katsuhisa ^c   Ohta, Tetsuo ^a   Nakanuma, Yasuni ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

Differential diagnosis; Hepatocellular carcinoma; Intrahepatic cholangiocarcinoma; SAGE

Indexed keywords

BIGLYCAN; CLAUDIN 4; COMPLEMENTARY DNA; SOMATOMEDIN BINDING PROTEIN 5; TUMOR MARKER;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA LIBRARY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GENE;

AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 46249109809     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.03.025     Document Type: Article

References (36)

1. Shaib Y., and El-Serag H.B. The epidemiology of cholangiocarcinoma. Semin Liver Dis 24 (2004) 115-125
2. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 33 (2001) 1353-1357
3. Taylor-Robinson S.D., Toledano M.B., Arora S., Keegan T.J., Hargreaves S., Beck A., et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 48 (2001) 816-820
4. Khan S.A., Taylor-Robinson S.D., Toledano M.B., Beck A., Elliott P., and Thomas H.C. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 37 (2002) 806-813
5. Davila J.A., and El-Serag H.B. Cholangiocarcinoma: the "other" liver cancer on the rise. Am J Gastroenterol 97 (2002) 3199-3200
6. Marrero J.A., and Lok A.S. Newer markers of hepatocellular carcinoma. Gastroenterology 127 (2004) S113-S119
7. Johnson D.E., Herndier B.G., Medeiros L.J., Warnke R.A., and Rouse R.V. The diagnostic utility of the keratin profiles of hepatocellular carcinoma and cholangiocarcinoma. Am J Surg Pathol 12 (1988) 187-197
8. Lai Y.S., Thung S.N., Gerber M.A., Chen M.L., and Schaffner F. Expression of cytokeratins in normal and diseased livers and in primary liver carcinomas. Arch Pathol Lab Med 113 (1989) 134-138
9. Maeda T., Adachi E., Kajiyama K., Sugimachi K., and Tsuneyoshi M. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analyses of clinicopathologic features. Hum Pathol 26 (1995) 956-964
10. Altmannsberger M., Weber K., Holscher A., Schauer A., and Osborn M. Antibodies to intermediate filaments as diagnostic tools: human gastrointestinal carcinomas express prekeratin. Lab Invest 46 (1982) 520-526
11. Saintigny P., Coulon S., Kambouchner M., Ricci S., Martinot E., Danel C., et al. Real-time RT-PCR detection of CK19, CK7 and MUC1 mRNA for diagnosis of lymph node micrometastases in non small cell lung carcinoma. Int J Cancer 115 (2005) 777-782
12. Khan S.A., Davidson B.R., Goldin R., Pereira S.P., Rosenberg W.M., Taylor-Robinson S.D., et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 51 (2002) VI1-VI9
13. Gores G.J. Cholangiocarcinoma: current concepts and insights. Hepatology 37 (2003) 961-969
14. Lódi C., Szabó E., Holczbauer A., Batmunkh E., Szi{dotless}́jártó A., Kupcsulik P., et al. Claudin-4 differentiates biliary tract cancers from hepatocellular carcinomas. Modern Pathol 19 (2006) 460-469
15. Velculescu V.E., Zhang L., Vogelstein B., and Kinzler K.W. Serial analysis of gene expression. Science 270 (1995) 484-487
16. Yamashita T., Hashimoto S., Kaneko S., Nagai S., Toyoda N., Suzuki T., et al. Comprehensive gene expression profile of a normal human liver. Biochem Biophys Res Commun 269 (2000) 110-116
17. Yamashita T., Kaneko S., Hashimoto S., Sato T., Nagai S., Toyoda N., et al. Serial analysis of gene expression in chronic hepatitis C and hepatocellular carcinoma. Biochem Biophys Res Commun 282 (2001) 647-654
18. Kawai H.F., Kaneko S., Honda M., Shirota Y., and Kobayashi K. Alpha-fetoprotein-producing hepatoma cell lines share common expression profiles of genes in various categories demonstrated by cDNA microarray analysis. Hepatology 33 (2001) 676-691
19. Shirota Y., Kaneko S., Honda M., Kawai H.F., and Kobayashi K. Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays. Hepatology 33 (2001) 832-840
20. Makuuchi M., Belghiti J., Belli G., Fan S.T., Lau J.W., Ringe B., et al. IHPBA concordant classification of primary liver cancer: working group report. J Hepatobiliary Pancreat Surg 10 (2003) 26-30
21. Yano H., Maruiwa M., Iemura A., Mizogichi A., and Kojiro M. Establishment and characterization of a new human extrahepatic bile duct carcinoma cell line (KMBC). Cancer 69 (1992) 1664-1673
22. Kim J., Kim J., Yoon S., Joo J., Lee Y., Lee K., et al. S100A6 protein as a marker for differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma. Hepatol Res 23 (2002) 274-286
23. Lichtinghagen R., Helmbrecht T., Arndt B., and Böker K.H. Expression pattern of matrix metalloproteinases in human liver. Eur J Clin Chem Clin Biochem 33 (1995) 65-71
24. Miwa S., Miyagawa S., Soeda J., and Kawasaki S. Matrix metalloproteinase-7 expression and biologic aggressiveness of cholangiocellular carcinoma. Cancer 94 (2002) 428-434
25. Kumble K.D., Hirota M., Pour P.M., and Vishwanatha J.K. Enhanced levels of annexins in pancreatic carcinoma cells of Syrian hamsters and their intrapancreatic allografts. Cancer Res 52 (1992) 163-167
26. Emoto K., Sawada H., Yamada Y., Fujimoto H., Takahama Y., Ueno M., et al. Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res 21 (2001) 1339-1345
27. Emoto K., Yamada Y., Sawada H., Fujimoto H., Ueno M., Takayama T., et al. Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer 92 (2001) 1419-1426
28. Ohuchida K., Mizumoto K., Ohhashi S., Yamaguchi H., Konomi H., Nagai E., et al. S100A11, a putative tumour suppressor gene, is overexpressed in pancreatic carcinogenesis. Clin Cancer Res 12 (2006) 5417-5422
29. Cai L., Mu L.N., Lu H., Lu Q.Y., You N.C., Yu S.Z., et al. Dietary selenium intake and genetic polymorphisms of the GSTP1 and p53 genes on the risk of esophageal squamous cell carcinoma. Cancer Epidemiol Bio Prev 15 (2006) 294-300
30. Xu L.L., Shi Y., Petrovics G., Sun C., Makarem M., Zhang W., et al. PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. Cancer Res 63 (2003) 4299-4304
31. ] Karahan N., Güney M., Oral B., Kapucuoglu N., and Mungan T. CD24 expression is a poor prognostic marker in endometrial carcinoma. Eur J Gynaecol Oncol 27 (2006) 500-504
32. Wegrowski Y., Pillarisetti J., Danielson K.G., Suzuki S., and Iozzo R.V. The murine biglycan: complete cDNA cloning, genomic organization, promoter function, and expression. Genomics 30 (1995) 8-17
33. Hogemann B., Edel G., Schwarz K., Krech R., and Kresse H. Expression of biglycan, decorin and proteoglycan-100/CSF-1 in normal and fibrotic human liver. Pathol Res Pract 193 (1997) 747-751
34. Schneider M.R., Wolf E., Hoeflich A., and Lahm H. IGF-binding protein-5: flexible player in the IGF system and effector on its own. J Endocrinol 172 (2002) 423-440
35. Butt A.J., Dickson K.A., McDougall F., and Baxter R.C. Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem 278 (2003) 29676-29685
36. Katahira J., Sugiyama H., Inoue N., Horiguchi Y., Matsuda M., and Sugimoto N. Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. J Biol Chem 272 (1997) 26652-26658